HBM HOLDINGS-B Forms Strategic Partnership with Bristol Myers Squibb, Potentially Earning Up to US$1.035B in Milestone Payments and Royalties
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Source: aastocks
Stock Performance: HBM HOLDINGS-B (02142.HK) experienced a decline of 3.849%, with a short selling amount of $12.54 million and a ratio of 21.210%.
Strategic Collaboration: HBM HOLDINGS-B has entered a multi-year global collaboration with Bristol Myers Squibb to develop next-generation multi-specific antibodies.
Financial Terms: The agreement could yield HBM HOLDINGS-B up to $90 million in initial payments, with potential development and commercial milestones totaling up to $1.035 billion.
Royalty Structure: HBM HOLDINGS-B may also receive tiered royalties if Bristol Myers Squibb decides to advance all potential programs under the collaboration.
Analyst Views on 02142
Wall Street analysts forecast 02142 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02142 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 14.380
Low
Averages
High
Current: 14.380
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
